PHI establish US subsidiary to foster US partnerships
As part of the ongoing expansion of activities on the US market, the Board of Directors of Phase Holographic Imaging (PHI) has initiated the process of establishing a fully owned subsidiary in the US.In February PHI signed a technology assessment agreement with a major US-based supplier of antibodies for cancer immunotherapy use. A joint seminar recently made it clear how exceptionally well the companies’ products complement each other. Together the respective product lines offer a complete solution to both activate immune cells and to study the effect of the activation by quantifying the
